NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Rejuvenate Biomed

Rejuvenate Biomed

Private
DiepenbeekHealthcare & Life Scienceshttps://www.rejuvenatebiomed.com/en

Last Round

Series B

Oct 12, 2021

Total Funding Raised

$23.11M

Company Overview

Rejuvenate Biomed is a biotechnology company that develops combination drugs to treat age-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

combination drugsage-related diseaselongevity biotechAI drug discoverysarcopeniadrug repurposingdrug discovery platformclinical stage biotechgerosciencein silico discoverynetwork biologyin vivo screeningC. elegans screeningsmall molecules

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rejuvenate Biomed Comparables

Compare Rejuvenate Biomed with similar companies based on industry and business-model similarity.

Rejuvenate Biomed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Biophytis SA
82%
BioAge Labs
76%
Epirium Bio
71%

Rejuvenate Biomed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 12, 2021
Series AMar 2, 2021
GrantAug 10, 2018
AcceleratorMar 1, 2018
SeedNov 1, 2017

Key People

Founding team and executive leadership

Ann Belien

Founder and CEO

Founding Team

Lizzy-Anne Neven

Chief Financial Officer

Executive Team

Rejuvenate Biomed Investors

Notable investors and investment history

Rejuvenate Biomed investors
InvestorRounds
Vesalius Biocapital PartnersSeries B
VLAIOSeries A, Grant
Johnson & Johnson Innovation - JLABSAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 2, 2021

    Raised $3.84M led by Vesalius BioCapital.

  • Aug 10, 2018

    $529K grant received from VLAIO.

Rejuvenate Biomed Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rejuvenate Biomed Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rejuvenate Biomed's valuation, stock price, and market status.

Firmographic Details

HeadquartersDiepenbeek
Employee Range15
Year Founded2017
Last FundingOct 12, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.